West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. Asian Pacific Journal of Cancer Prevention 1513-7368 19 6 2018 06 01 Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study 1547 1551 63276 10.22034/APJCP.2018.19.6.1547 EN Farzaneh Ashrafi Department of Hematology and Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Sarah Mousavi Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy,, Isfahan University of Medical Sciences, Isfahan, Iran. Mohammad Karimi Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. Journal Article 2017 10 02 Background: Cancer-related fatigue (CRF) is very common and can be experienced at all stages of disease and in<br />survivors. CRF causes patients more distress than pain or nausea and vomiting. Different pharmacologic interventions<br />have been evaluated for the management of CRF. The purpose of this study was to determine the efficacy of bupropion<br />sustained release (SR) as a treatment for fatigue in patients with cancer. Methods: In this randomized, double-blind,<br />placebo-controlled trial, patients with fatigue due to cancer were randomly assigned to either 150mg daily of bupropion<br />SR or matching placebo. The primary endpoint was the changes in average daily fatigue from baseline to week 4 using<br />the Functional Assessment of Chronic Illness-therapy- Fatigue (FACIT-F) questionnaire. Results: 40 patients were<br />randomly assigned to treatment with bupropion SR or placebo (20 in each group). Analysis of covariance (ANCOVA)<br />showed a significant improvement in fatigue and quality of life in the bupropion group compared to baseline (P=0.000).<br />Secondary outcome, including depression, severity of fatigue and performance status didn’t show significant difference<br />between groups. Generally, bupropion SR was tolerated well. Conclusion: Four weeks of 150 mg bupropion SR<br />improve fatigue significantly in cancer patients. Bupropion has potential as an effective and safe pharmaceutical agent<br />for treating CRF. https://journal.waocp.org/article_63276_b9e29c8dbc52ce5ea596fde7189145ec.pdf